Involvement of protein degradation by the ubiquitin proteasome system in opiate addictive behaviors

Neuropsychopharmacology

Volumn 38, Issue 4, 2013, Pages 596-604

  Massaly, Nicolas ^a,b,c   Dahan, Lionel ^a,b   Baudonnat, Mathieu ^d   Hovnanian, Caroline ^a,b   Rekik, Khaoula ^a,b   Solinas, Marcello ^e   David, Vincent ^d   Pech, Stéphane ^a,b   Zajac, Jean Marie ^a,c   Roullet, Pascal ^a,b   Mouledous, Lionel ^a,c   Frances, Bernard ^a,c  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b Université Paul Sabatier   (France)

^c INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e UNIVERSITÉ DE POITIERS   (France)

Author keywords

behavior; nucleus accumbens; opiate; proteasome; protein degradation; reinforcement

Indexed keywords

CASPASE 3; LACTACYSTIN; MORPHINE; UBIQUITIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISCRIMINATION LEARNING; DOSE RESPONSE; DRUG SELF ADMINISTRATION; ENZYME ACTIVITY; IN VIVO STUDY; LOCOMOTION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; OPIATE ADDICTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN MODIFICATION; RAT; REWARD; UBIQUITIN PROTEASOME SYSTEM; UBIQUITINATION; VENTRAL TEGMENTUM;

ANIMALS; BEHAVIOR, ADDICTIVE; MALE; MICE; MICE, INBRED C57BL; MORPHINE; OPIOID-RELATED DISORDERS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; RATS; RATS, SPRAGUE-DAWLEY; SELF ADMINISTRATION; UBIQUITIN;

EID: 84873739541     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.217     Document Type: Article

References (44)

1. Alberini CM (2005). Mechanisms of memory stabilization: are consolidation and reconsolidation similar or distinct processes? Trends Neurosci 28: 51-56.
2. Ande SR, Chen J, Maddika S (2009). The ubiquitin pathway: an emerging drug target in cancer therapy. Eur J Pharmacol 625: 199-205.
3. Artinian J, McGauran AM, De Jaeger X, Mouledous L, Frances B, Roullet P (2008). Protein degradation, as with protein synthesis, is required during not only long-term spatial memory consolidation but also reconsolidation. Eur J Neurosci 27: 3009-3019.
4. Badiani A, Robinson TE (2004). Drug-induced neurobehavioral plasticity: the role of environmental context. Behav Pharmacol 15: 327-339.
5. Baudonnat M, Guillou JL, Husson M, Vandesquille M, Corio M, Decorte L et al 2011). Disrupting effect of drug-induced reward on spatial but not cue-guided learning: implication of the striatal protein kinase A/cAMP response element-binding protein pathway. J Neurosci 31: 16517-16528.
6. Belin D, Jonkman S, Dickinson A, Robbins TW, Everitt BJ (2009). Parallel and interactive learning processes within the basal ganglia: relevance for the understanding of addiction. Behav Brain Res 199: 89-102.
7. Cardinal RN, Everitt BJ (2004). Neural and psychological mechanisms underlying appetitive learning: links to drug addiction. Curr Opin Neurobiol 14: 156-162.
8. Carle TL, Ohnishi YN, Ohnishi YH, Alibhai IN, Wilkinson MB, Kumar A et al (2007). Proteasome-dependent and-independent mechanisms for FosB destabilization: identification of FosB degron domains and implications for DeltaFosB stability. Eur J Neurosci 25: 3009-3019.
9. Chauvet C, Lardeux V, Goldberg SR, Jaber M, Solinas M (2009). Environmental enrichment reduces cocaine seeking and reinstatement induced by cues and stress but not by cocaine. Neuropsychopharmacology 34: 2767-2778.
10. Chen D, Frezza M, Schmitt S, Kanwar J, Ping DQ 2011). Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 11: 239-253.
11. Citri A, Soler-Llavina G, Bhattacharyya S, Malenka RC (2009). N-methyl-D-aspartate receptor-and metabotropic glutamate receptor-dependent long-term depression are differentially regulated by the ubiquitin-proteasome system. Eur J Neurosci 30: 1443-1450.
12. Conrad KL, Tseng KY, Uejima JL, Reimers JM, Heng LJ, Shaham Y et al (2008). Formation of accumbens GluR2-lacking AMPA receptors mediates incubation of cocaine craving. Nature 454: 118-121.
13. Contet C, Filliol D, Matifas A, Kieffer BL (2008). Morphine-induced analgesic tolerance, locomotor sensitization and physical dependence do not require modification of mu opioid receptor, cdk5 and adenylate cyclase activity. Neuropharmacology 54: 475-486.
14. David V, Durkin TP, Cazala P (2002). Differential effects of the dopamine D2/D3 receptor antagonist sulpiride on self-administration of morphine into the ventral tegmental area or the nucleus accumbens. Psychopharmacology 160: 307-317.
15. Dong C, Upadhya SC, Ding L, Smith TK, Hegde AN (2008). Proteasome inhibition enhances the induction and impairs the maintenance of late-phase long-term potentiation. Learn Mem 15: 335-347.
16. Dunah AW, Standaert DG (2001). Dopamine D1 receptordependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J Neurosci 21: 5546-5558.
17. Fioravante D, Byrne JH 2011). Protein degradation and memory formation. Brain Res Bull 85: 14-20.
18. Fonseca R, Vabulas RM, Hartl FU, Bonhoeffer T, Nagerl UV (2006). A balance of protein synthesis and proteasome-dependent degradation determines the maintenance of LTP. Neuron 52: 239-245.
19. Girault JA, Valjent E, Caboche J, Herve D (2007). ERK2: a logical AND gate critical for drug-induced plasticity? Curr Opin Pharmacol 7: 77-85.
20. Hegde AN (2010). The ubiquitin-proteasome pathway and synaptic plasticity. Learn Mem 17: 314-327.
21. Hyman SE, Malenka RC, Nestler EJ (2006). Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 29: 565-598.
22. Kaang BK, Choi JH 2011). Protein degradation during reconsolidation as a mechanism for memory reorganization. Front Behav Neurosci 5: 2.
23. Karpova A, Mikhaylova M, Thomas U, Knopfel T, Behnisch T (2006). Involvement of protein synthesis and degradation in long-term potentiation of Schaffer collateral CA1 synapses. J Neurosci 26: 4949-4955.
24. Kasanetz F, Deroche-Gamonet V, Berson N, Balado E, Lafourcade M, Manzoni O et al (2010). Transition to addiction is associated with a persistent impairment in synaptic plasticity. Science 328: 1709-1712.
25. Kauer JA, Malenka RC (2007). Synaptic plasticity and addiction. Nat Rev Neurosci 8: 844-858.
26. Kelley AE (2004). Memory and addiction; shared neural circuitry and molecular mechanisms. Neuron 44: 161-179.
27. Kisselev AF, Goldberg AL (2001). Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8: 739-758.
28. Lee SH, Choi JH, Lee N, Lee HR, Kim JI, Yu NK et al (2008). Synaptic protein degradation underlies destabilization of retrieved fear memory. Science 319: 1253-1256.
29. Lopez-Salon M, Alonso M, Vianna MR, Viola H, Mello e Souza T, Izquierdo I et al (2001). The ubiquitin-proteasome cascade is required for mammalian long-term memory formation. Eur J Neurosci 14: 1820-1826.
30. Mameli M, Halbout B, Creton C, Engblom D, Parkitna JR, Spanagel R et al (2009). Cocaine-evoked synaptic plasticity: persistence in the VTA triggers adaptations in the NAc. Nat Neurosci 12: 1036-1041.
31. Marchand S, Betourne A, Marty V, Daumas S, Halley H, Lassalle JM et al (2006). A neuropeptide FF agonist blocks the acquisition of conditioned place preference to morphine in C57Bl/6J mice. Peptides 27: 964-972.
32. McClung CA, Nestler EJ (2008). Neuroplasticity mediated by altered gene expression. Neuropsychopharmacology 33: 3-17.
33. Mouledous L, Neasta J, Uttenweiler-Joseph S, Stella A, Matondo M, Corbani M et al (2005). Long-term morphine treatment enhances proteasome-dependent degradation of G beta in human neuroblastoma SH-SY5Y cells: correlation with onset of adenylate cyclase sensitization. Mol Pharmacol 68: 467-476.
34. Mouledous L, Frances B, Zajac JM (2010). Modulation of basal and morphine-induced neuronal activity by a NPFF(2) selective agonist measured by c-Fos mapping of the mouse brain. Synapse 64: 672-681.
35. Moulédous L, Merker S, Neasta J, Roux B, Zajac JM, Mollereau C (2008). Neuropeptide FF-sensitive confinement of mu opioid receptor does not involve lipid rafts in SH-SY5Y cells. Biochem Biophys Res Commun 373: 80-84.
36. Pascoli V, Turiault M, Lüscher C 2011). Reversal of cocaineevoked synaptic potentiation resets drug-induced adaptive behaviour. Nature 481: 71-75.
37. Robbins TW, Ersche KD, Everitt BJ (2008). Drug addiction and the memory systems of the brain. Ann NY Acad Sci 1141: 1-21.
38. Robbins TW, Everitt BJ (1996). Neurobehavioural mechanisms of reward and motivation. Curr Opin Neurobiol 6: 228-236.
39. Sun X, Wolf ME (2009). Nucleus accumbens neurons exhibit synaptic scaling that is occluded by repeated dopamine preexposure. Eur J Neurosci 30: 539-550.
40. Tzschentke TM (1998). Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 56: 613-672.
41. Vanderschuren LJ, Kalivas PW (2000). Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology 151: 99-120.
42. Yang L, Wang S, Lim G, Sung B, Zeng Q, Mao J (2008a). Inhibition of the ubiquitin-proteasome activity prevents glutamate transporter degradation and morphine tolerance. Pain 140: 472-478.
43. Yang L, Wang S, Sung B, Lim G, Mao J (2008b). Morphine induces ubiquitin-proteasome activity and glutamate transporter degradation. J Biol Chem 283: 21703-21713.
44. Zernig G, Wakonigg G, Madlung E, Haring C, Saria A (2004). Do vertical shifts in dose-response rate-relationships in operant conditioning procedures indicate "sensitization" to "drug wanting"? Psychopharmacology (Berl) 171: 349-351 author reply 352-363.